** Shares of Gilead Sciences GILD.O fall ~3% to $107 premarket
** U.S. health department is reviewing CDC's HIV prevention division for potential overlap with other agencies and might be at risk of a shut down
** Brokerage J.P. Morgan says CDC funding cuts are "not a positive" for GILD, but will not impact access to PrEP treatments, as the CDC is "not responsible for providing/reimbursing PrEP drugs, but rather works on PrEP research and education"
** PrEP are medications that prevent HIV infection
** Brokerage Jefferies does not expect that the potential CDC budget cuts of $1.3 bln will have a major impact on the closely-watched launch of GILD's long-acting PrEP medication lenacapavir
** Brokerage BMO Capital says cuts would only "incrementally slow revenue for some HIV treatments" for GILD and to a lesser degree Merck MRK.N
** GILD's HIV drugs brough in revenues of $19.6 billion last year, accounting for about 68% of total sales
** GILD gained 50.5%, MRK down 22% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.